These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33002673)

  • 1. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Tremblay D; Feld J; Dougherty M; Czaplinska T; Sanchez G; Kremyanskaya M; Bar-Natan M; Shih AH; Keyzner A; Mascarenhas J
    Leuk Res; 2020 Nov; 98():106456. PubMed ID: 33002673
    [No Abstract]   [Full Text] [Related]  

  • 2. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
    Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
    Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457
    [No Abstract]   [Full Text] [Related]  

  • 3. Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.
    Gangat N; Morsia E; Foran JM; Palmer JM; Elliott MA; Tefferi A
    Br J Haematol; 2020 Dec; 191(5):e120-e124. PubMed ID: 32945528
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
    Salhotra A; Aribi A; Ngo D; Zhang J; Sandhu K; Al-Malki M; Ali H; Koller P; Arslan S; Budde E; Khaled S; Dadwal S; Snyder DS; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
    Am J Hematol; 2021 Jun; 96(6):E196-E200. PubMed ID: 33719090
    [No Abstract]   [Full Text] [Related]  

  • 5. Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax.
    Cordella S; Giusti D; De Bellis E; Dargenio M; Creti' F; Lazzarotto D; Cattaneo C; Fracchiolla NS; Piccini M; Forghieri F; Pagano L; Candoni A
    Hematol Oncol; 2024 Sep; 42(5):e3310. PubMed ID: 39276390
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
    Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
    Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypomethylating agents and venetoclax in acute myeloid leukemia.
    DiNardo CD
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
    [No Abstract]   [Full Text] [Related]  

  • 8. Venetoclax with decitabine or azacitidine for AML.
    Das M
    Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
    Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
    Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
    Liao PW; Wang RC; Chen TC; Teng CJ
    Ann Hematol; 2021 May; 100(5):1333-1334. PubMed ID: 33439305
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
    Qu W; Lu J; Ji Y; He Z; Hou M; Li D; Yang Y; Liu D; Chen S
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):635-639. PubMed ID: 38430306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
    Blombery P; Lew TE; Dengler MA; Thompson ER; Lin VS; Chen X; Nguyen T; Panigrahi A; Handunnetti SM; Carney DA; Westerman DA; Tam CS; Adams JM; Wei AH; Huang DCS; Seymour JF; Roberts AW; Anderson MA
    Blood; 2022 Feb; 139(8):1198-1207. PubMed ID: 34469514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
    Arslan S; Zhang J; Dhakal P; Moran J; Naidoo N; Lombardi J; Pullarkat V; Stein AS; Marcucci G; Yaghmour G; Bhatt VR; Fathi AT; Aldoss I
    Am J Hematol; 2021 Mar; 96(3):E59-E63. PubMed ID: 33227142
    [No Abstract]   [Full Text] [Related]  

  • 17. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
    Venugopal S; Maiti A; DiNardo CD; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
    Am J Hematol; 2021 May; 96(5):E154-E157. PubMed ID: 33580980
    [No Abstract]   [Full Text] [Related]  

  • 18. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
    Karrar O; Abdelmagid M; Rana M; Iftikhar M; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Elliott MA; Mangaonkar A; Saliba A; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):E63-E66. PubMed ID: 38100217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies.
    Jeng MY; Dutta R; Tan IT; Zhang TY; Mannis GN
    Am J Hematol; 2020 Nov; 95(11):E305-E308. PubMed ID: 32744731
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
    Diao S; Nichols ED; DiNardo C; Konopleva M; Ning J; Qiao W; Maiti A; DiPippo AJ
    Am J Hematol; 2021 Mar; 96(3):E65-E68. PubMed ID: 33259075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.